[go: up one dir, main page]

GB0716160D0 - Materials and methods for treating cancers which express folate receptors - Google Patents

Materials and methods for treating cancers which express folate receptors

Info

Publication number
GB0716160D0
GB0716160D0 GBGB0716160.7A GB0716160A GB0716160D0 GB 0716160 D0 GB0716160 D0 GB 0716160D0 GB 0716160 A GB0716160 A GB 0716160A GB 0716160 D0 GB0716160 D0 GB 0716160D0
Authority
GB
United Kingdom
Prior art keywords
materials
methods
treating cancers
folate receptors
express folate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0716160.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOTRANSFORMATIONS Ltd
Original Assignee
BIOTRANSFORMATIONS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOTRANSFORMATIONS Ltd filed Critical BIOTRANSFORMATIONS Ltd
Priority to GBGB0716160.7A priority Critical patent/GB0716160D0/en
Publication of GB0716160D0 publication Critical patent/GB0716160D0/en
Priority to PCT/GB2008/002799 priority patent/WO2009024771A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0716160.7A 2007-08-17 2007-08-17 Materials and methods for treating cancers which express folate receptors Ceased GB0716160D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0716160.7A GB0716160D0 (en) 2007-08-17 2007-08-17 Materials and methods for treating cancers which express folate receptors
PCT/GB2008/002799 WO2009024771A2 (en) 2007-08-17 2008-08-18 Materials and methods for treating cancers which express folate receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0716160.7A GB0716160D0 (en) 2007-08-17 2007-08-17 Materials and methods for treating cancers which express folate receptors

Publications (1)

Publication Number Publication Date
GB0716160D0 true GB0716160D0 (en) 2007-09-26

Family

ID=38566627

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0716160.7A Ceased GB0716160D0 (en) 2007-08-17 2007-08-17 Materials and methods for treating cancers which express folate receptors

Country Status (2)

Country Link
GB (1) GB0716160D0 (en)
WO (1) WO2009024771A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN104822704B (en) * 2012-06-14 2020-02-14 医疗生物科学有限公司 Humanized antibodies against cluster of differentiation 3(CD3)
TW201446804A (en) * 2013-05-14 2014-12-16 Ambrx Inc Novel polypeptide small molecule conjugates and their uses
CA2913051C (en) 2013-05-28 2023-09-05 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
GB2528643A (en) * 2014-07-08 2016-02-03 Adc Biotechnology Ltd Method of synthesising ADCs
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
CN108348603B (en) * 2015-11-03 2023-12-29 Ambrx公司 anti-CD 3 folate conjugates and uses thereof
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
AU2017371225A1 (en) 2016-12-09 2019-05-16 Seagen Inc. Bivalent antibodies masked by coiled coils
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636015T2 (en) * 1995-05-03 2007-01-04 Bioenhancementsments Ltd. BIS-SPECIFIC ANTIBODIES IN WHICH THE BINDING ABILITY IS INHERITIZED BY A MEDIUM-SPLITABLE GROUP REVERSIBLE
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
GB0404187D0 (en) * 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
GB0605702D0 (en) * 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation

Also Published As

Publication number Publication date
WO2009024771A2 (en) 2009-02-26
WO2009024771A3 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
GB0716160D0 (en) Materials and methods for treating cancers which express folate receptors
IL242169A0 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
SI2429574T1 (en) Compositions and methods for treating hematologic cancers targeting the sirp - cd47 interaction
IL219060A (en) Toll-like receptors and agonist for treating cancer
GB2486598B (en) Downhole material retention apparatus
ZA201007446B (en) Tungsten rhenium compounds and composites and methods for forming the same
GB0704650D0 (en) Tissue classifying apparatus
IL197914A (en) Anti-ereg antibodies for treating cancer
EP2259796A4 (en) Materials and methods for improved immunoglycoproteins
GB201101957D0 (en) Oral cancer screening device
IL219331A0 (en) Method for treating androgrn receptor positive cancers
EP2152420A4 (en) Material reducing apparatus
ZA201005248B (en) 4-pyridinone compounds and their use for cancer
HRP20130642T1 (en) Methods and compositions for treating cancers
GB0706430D0 (en) Methods and apparatus for making composite materials
HK1156900A1 (en) Powder treating apparatus
EP2144888A4 (en) Methods for treating cancer
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
GB0723380D0 (en) Particle beam apparatus
PL2176002T3 (en) Cyclone apparatus
ZA201009066B (en) Materials and methods for suppressing and/or treating neurofibroma and related tumors
GB0823443D0 (en) Grinding apparatus
GB2458570B (en) Slurry distribution apparatus
EP2307573A4 (en) Methods for screening for compounds for treating cancer
GB0724851D0 (en) Shredding apparatus

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)